BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/130/0.1/20.09.24 Share Price

Warrant

P1YVI0

NLBNPIT1YVI0

Real-time Borsa Italiana 12:01:57 27/06/2024 BST
0.0125 EUR -3.85% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/130/0.1/20.09.24
Current month-92.66%
1 month-88.84%
Date Price Change
27/06/24 0.0125 -3.85%
26/06/24 0.013 -29.73%
25/06/24 0.0185 -11.90%
24/06/24 0.021 +16.67%
21/06/24 0.018 -36.84%

Real-time Borsa Italiana

Last update June 27, 2024 at 12:01 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
P1YVI0
ISINNLBNPIT1YVI0
Date issued 29/01/2024
Strike 130 $
Maturity 20/09/2024 (86 Days)
Parity 10 : 1
Emission price-
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 0.443
Lowest since issue 0.0125
Delta0.02x
Omega 13.63
Premium57.71x
Gearing593.25x
Moneyness 0.6348
Difference Strike 47.48 $
Difference Strike %+36.52%
Spread 0.009
Spread %51.43%
Theoretical value 0.0130
Implied Volatility 43.61 %
Total Loss Probability 98.63 %
Intrinsic value 0.000000
Present value 0.0130
Break even 130.14 €
Theta-0x
Vega0x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
77.26 EUR
Average target price
103.5 EUR
Spread / Average Target
+33.99%
Consensus
  1. Stock Market
  2. Warrants
  3. P1YVI0 Warrant